Cargando…

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy

BACKGROUND AND AIM: Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocellular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebik, Berat, Aygan, Mustafa, Tuncel, Elif Tugba, Kacmaz, Huseyin, Ekin, Nazim, Arpa, Medeni, Yalcin, Kendal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510740/
https://www.ncbi.nlm.nih.gov/pubmed/36177099
http://dx.doi.org/10.14744/hf.2022.2022.0016
_version_ 1784797506389934080
author Ebik, Berat
Aygan, Mustafa
Tuncel, Elif Tugba
Kacmaz, Huseyin
Ekin, Nazim
Arpa, Medeni
Yalcin, Kendal
author_facet Ebik, Berat
Aygan, Mustafa
Tuncel, Elif Tugba
Kacmaz, Huseyin
Ekin, Nazim
Arpa, Medeni
Yalcin, Kendal
author_sort Ebik, Berat
collection PubMed
description BACKGROUND AND AIM: Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocellular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV patients who achieved a sustained virologic response (SVR) following DAA therapies. MATERIALS AND METHODS: The medical data of patients who were diagnosed with HCV and received DAA therapy in two tertiary centers in Turkey were retrospectively collected. RESULTS: Among them, 75 patients (52.4%) were noncirrhotic and 68 patients (47.6%) were cirrhotic. The overall SVR rate was 97.2% (139/143). It was 100% in noncirrhotic and 94.1% in cirrhotic patients. HCC was developed in 5 (7.4%) patients, all of whom had baseline cirrhosis. The annual rate of HCC occurrence was 2.94%, and the 5-year cumulative incidence of HCC was 7.3%. The mean Child-Pugh score (CPS) and Model for End-Stage Liver Disease (MELD) score significantly decreased after DAA treatment (CPS 7.0 vs 5.9, p=0.001; MELD 10.8 vs 9.5, p=0.003). CONCLUSION: There was no significant increase in the rate of HCC in cirrhotic HCV patients treated with DAAs. This treatment led to a remarkably high SVR rate and lowered CPS and MELD scores in cirrhotic HCV patients.
format Online
Article
Text
id pubmed-9510740
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-95107402022-09-28 Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy Ebik, Berat Aygan, Mustafa Tuncel, Elif Tugba Kacmaz, Huseyin Ekin, Nazim Arpa, Medeni Yalcin, Kendal Hepatol Forum Research Article BACKGROUND AND AIM: Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocellular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV patients who achieved a sustained virologic response (SVR) following DAA therapies. MATERIALS AND METHODS: The medical data of patients who were diagnosed with HCV and received DAA therapy in two tertiary centers in Turkey were retrospectively collected. RESULTS: Among them, 75 patients (52.4%) were noncirrhotic and 68 patients (47.6%) were cirrhotic. The overall SVR rate was 97.2% (139/143). It was 100% in noncirrhotic and 94.1% in cirrhotic patients. HCC was developed in 5 (7.4%) patients, all of whom had baseline cirrhosis. The annual rate of HCC occurrence was 2.94%, and the 5-year cumulative incidence of HCC was 7.3%. The mean Child-Pugh score (CPS) and Model for End-Stage Liver Disease (MELD) score significantly decreased after DAA treatment (CPS 7.0 vs 5.9, p=0.001; MELD 10.8 vs 9.5, p=0.003). CONCLUSION: There was no significant increase in the rate of HCC in cirrhotic HCV patients treated with DAAs. This treatment led to a remarkably high SVR rate and lowered CPS and MELD scores in cirrhotic HCV patients. Kare Publishing 2022-09-23 /pmc/articles/PMC9510740/ /pubmed/36177099 http://dx.doi.org/10.14744/hf.2022.2022.0016 Text en © Copyright 2022 by Hepatology Forum https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Research Article
Ebik, Berat
Aygan, Mustafa
Tuncel, Elif Tugba
Kacmaz, Huseyin
Ekin, Nazim
Arpa, Medeni
Yalcin, Kendal
Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy
title Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy
title_full Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy
title_fullStr Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy
title_full_unstemmed Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy
title_short Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy
title_sort development of hepatocellular carcinoma in patients with chronic hepatitis c who had sustained viral response following direct-acting antiviral therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510740/
https://www.ncbi.nlm.nih.gov/pubmed/36177099
http://dx.doi.org/10.14744/hf.2022.2022.0016
work_keys_str_mv AT ebikberat developmentofhepatocellularcarcinomainpatientswithchronichepatitiscwhohadsustainedviralresponsefollowingdirectactingantiviraltherapy
AT ayganmustafa developmentofhepatocellularcarcinomainpatientswithchronichepatitiscwhohadsustainedviralresponsefollowingdirectactingantiviraltherapy
AT tunceleliftugba developmentofhepatocellularcarcinomainpatientswithchronichepatitiscwhohadsustainedviralresponsefollowingdirectactingantiviraltherapy
AT kacmazhuseyin developmentofhepatocellularcarcinomainpatientswithchronichepatitiscwhohadsustainedviralresponsefollowingdirectactingantiviraltherapy
AT ekinnazim developmentofhepatocellularcarcinomainpatientswithchronichepatitiscwhohadsustainedviralresponsefollowingdirectactingantiviraltherapy
AT arpamedeni developmentofhepatocellularcarcinomainpatientswithchronichepatitiscwhohadsustainedviralresponsefollowingdirectactingantiviraltherapy
AT yalcinkendal developmentofhepatocellularcarcinomainpatientswithchronichepatitiscwhohadsustainedviralresponsefollowingdirectactingantiviraltherapy